Protein

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer or lung cancer, for monitoring the effectiveness of colorectal cancer or lung cancer treatment, and for drug development.

1 - 61 . (canceled) 
     
     
         62 . A method of treating or preventing colorectal cancer or lung cancer which comprises administering to a subject in need thereof a therapeutically effective amount of a composition comprising an affinity reagent capable of specific binding to OGTA019, or a fragment or derivative thereof, and a pharmaceutically acceptable diluent or carrier. 
     
     
         63 . An affinity reagent capable of specific binding to OGTA019 or a fragment thereof. 
     
     
         64 . An affinity reagent according to  claim 63  which further comprises a diagnostic or a therapeutic moiety. 
     
     
         65 . An affinity reagent according to  claim 63  wherein said affinity reagent is selected from the group consisting of an antibody, an Affibody, a Nanobody, an Unibody or a Domain Antibody. 
     
     
         66 . An affinity reagent according to  claim 65 , wherein said antibody is a monoclonal antibody or a fragment thereof. 
     
     
         67 . An affinity reagent according to  claim 64  wherein said affinity reagent is selected from the group consisting of an antibody, an Affibody, a Nanobody, an Unibody or a Domain Antibody. 
     
     
         68 . An affinity reagent according to  claim 67 , wherein said antibody is a monoclonal antibody or a fragment thereof. 
     
     
         69 . A pharmaceutical composition comprising a therapeutically effective amount of an affinity reagent according to  claim 63 . 
     
     
         70 . A kit comprising an affinity reagent according to  claim 63 . 
     
     
         71 . A method comprising
 a) identifying the presence or absence of OGTA019, or a fragment thereof, or   b) determining whether OGTA019, or a fragment thereof, is increased/decreased in a biological sample obtained from said human subject, whereby if a) the presence of OGTA019 is indicative of colorectal cancer or lung cancer or if b) increased OGTA019 is indicative of colorectal cancer or lung cancer.   
     
     
         72 . A method as defined in  claim 71 , wherein the method comprises an immunoassay step utilising an affinity reagent capable of specific binding to OGTA019 or a fragment thereof. 
     
     
         73 . A method for screening, diagnosis or prognosis of colorectal cancer or lung cancer in a subject or for monitoring the effect of an anti-colorectal cancer or an anti-lung cancer drug or therapy administered to a subject, comprising: in a sample from the subject, quantitatively detecting OGTA019, wherein the step of quantitatively detecting comprises testing the sample, said step of testing comprising:
 a) contacting the sample with an affinity reagent as defined in  claim 63 ; and   b) detecting whether binding has occurred between the affinity reagent and at least one species in the sample.   
     
     
         74 . A method according to  claim 71  wherein the sample is a sample of colon or lung tissue. 
     
     
         75 . A method according to  claim 73  wherein the sample is a sample of colon or lung tissue. 
     
     
         76 . A method according to  claim 71 , wherein the method of determining the abundance of OGTA019 comprises imaging said labelled antibodies or Affibodies. 
     
     
         77 . A method according to  claim 76 , wherein said imaging comprises carrying out immunohistochemistry to determine the localisation of colorectal cancer or lung cancer cells, by the use of labeled affinity reagents capable of specific binding to OGTA019 or a fragment thereof. 
     
     
         78 . A method according to  claim 62  wherein OGTA019 or a fragment or derivative thereof is defined by SEQ ID No: 1 or comprises one or more sequences of SEQ ID Nos: 2-8.